New data from a Phase I clinical trial shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment. "Given the deadly nature of this disease, three-year survival is rarely reported in the recurrent setting. It is notable that the survival benefit was seen across a range of patients and not just limited to patients with specific genetic mutations," said Chen. "This finding indicates that many patients could benefit from this treatment." As Chen explained at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics two...
